High-affinity binding to gas6
US-2016266136-A1 · Sep 15, 2016 · US
Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy
US9822347B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9822347-B2 |
| Application number | US-201314650854-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 12, 2013 |
| Priority date | Dec 14, 2012 |
| Publication date | Nov 21, 2017 |
| Grant date | Nov 21, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
First claim
Opening claim text (preview).
What is claimed is: 1. An inhibitor of GAS6, wherein the inhibitor is a soluble AXL variant polypeptide, wherein said soluble AXL variant polypeptide: lacks the AXL transmembrane domain, lacks a functional fibronectin (FN) domain, has an Ig1 domain, and an Ig2 domain, comprises a set of amino acid substitutions relative to SEQ ID NO:1 selected from Gly32Ser, Asp87Gly, Val92Ala, and Gly127Arg; or Gly32Ser, Ala72Val, Asp87Gly, Val92Ala, and Gly127Arg, comprises an Fc domain linked to the AXL variant polypeptide by a linker comprising from 1 to 5 (GLY) 4 SER (SEQ ID NO:10) units; and wherein said AXL variant polypeptide exhibits increased affinity of binding to GAS6 compared to wild-type AXL (SEQ ID NO:1). 2. The inhibitor of claim 1 , in a pharmaceutically acceptable excipient. 3. A method of reducing growth or metastasis of a tumor that expresses GAS6, the method comprising administering to a patient with a tumor that expresses GAS6 an effective dose of the inhibitor of claim 1 .
Assignees
Inventors
Classifications
specific for metastasis · CPC title
Antineoplastic agents · CPC title
fusions with soluble part of a cell surface receptor, "decoy receptors" · CPC title
Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto · CPC title
Receptor protein-tyrosine kinase (2.7.10.1) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9822347B2 cover?
- Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
- Who is the assignee on this patent?
- Univ Leland Stanford Junior, Aravive Biologics Inc
- What technology area does this patent fall under?
- Primary CPC classification C12N9/12. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).